Building on Novartis' longstanding strength in Neuroscience plus the recent explosion of scientific knowledge and technology catalyzing the field, teams are tackling diseases that seemed intractable just five years ago. The time is finally ripe for pathways-based rational drug discovery in many neurological indications. Novartis is hiring 70 associates by 2014 and 30 more during the next few years at our Cambridge, MA global research headquarters to help patients with neuropsychiatric and neurodegenerative diseases.
We are taking advantage of new tools, including induced pluripotent stem cells and optogenetics, and of academic collaborations to sift through genetic clues, build disease models and deepen our understanding of neural circuits. Our research in Neuroscience aims to leverage the latest advances in human genetics to probe the underlying pathophysiology of diseases, such as Autism, Schizophrenia and Bipolar disorder, as well as, Parkinson's disease, Alzheimer's disease and Frontotemporal Dementias.
Learn more from Ricardo Dolmetsch, Ph.D., NIBR's new Global Head of Neuroscience.